Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
about
New and emerging targeted therapies for cystic fibrosisEngineering large animal models of human diseaseCurrent translational and clinical practices in hematopoietic cell and gene therapyOvine pulmonary adenocarcinoma: a large animal model for human lung cancerHighly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapyBarriers to inhaled gene therapy of obstructive lung diseases: A reviewImpact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization.Nanotechnology approaches for inhalation treatment of fibrosis.Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy.Cystic Fibrosis Gene Therapy in the UK and Elsewhere.Differential bioreactivity of neutral, cationic and anionic polystyrene nanoparticles with cells from the human alveolar compartment: robust response of alveolar type 1 epithelial cellsAdvances in cell and gene-based therapies for cystic fibrosis lung diseaseEvaluation of New Fluorescent Lipophosphoramidates for Gene Transfer and Biodistribution Studies after Systemic AdministrationA Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose TrialIntrapulmonary Versus Nasal Transduction of Murine Airways With GP64-pseudotyped Viral VectorsGene delivery to the airwayAirway deposition of nebulized gene delivery nanocomplexes monitored by radioimaging agents.Inhaled biopharmaceutical drug development: nonclinical considerations and case studies.Synthetic vectors for gene delivery: An overview of their evolution depending on routes of administration.Genetic medicines for CF: Hype versus reality.Arsonium-containing lipophosphoramides, poly-functional nano-carriers for simultaneous antibacterial action and eukaryotic cell transfection.Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis.A novel translational model for fetoscopic intratracheal delivery of nanoparticles in piglets.Correction of the ΔF508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene by Zinc-Finger Nuclease Homology-Directed Repair.Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.A lung segmental model of chronic Pseudomonas infection in sheep.Gene therapy in the clinics: shifting into the next gear.Assessment of the nuclear pore dilating agent trans-cyclohexane-1,2-diol in differentiated airway epithelium.Rapid identification of novel functional promoters for gene therapy.A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
P2860
Q26749278-5463D3B4-C683-4085-B126-3F38B6BB5CC7Q26785547-A569B8BC-7054-422B-98E4-F064258340DCQ27024456-C999FE07-B75E-41A1-B701-7457E85BE781Q28088774-42B7B8BF-6BA3-4ED9-B0E5-A84305C43360Q28383844-C77BAD32-9D74-464A-BB31-409CC4906EC8Q29248141-EF157FDF-2C80-4A61-89CD-700773286535Q30372632-2D26CEF8-5DF9-4769-9C3D-9F71C839A5CDQ30437330-8F268087-DA8E-4285-A2C0-B21976172065Q34449624-4CD20214-216E-4B91-8B25-264E0994FC32Q34483772-059E73DD-ED6E-4C2D-91AC-C18EC5B25CA6Q34747045-9D631085-66B1-4095-9CF3-82A9E44C0090Q35641704-B942F3F4-3D15-425E-BD8A-5074725D99C5Q35680554-A8843851-4451-49EC-9CF7-726374EB9F3EQ36014033-F5E45350-1C37-4CC0-AB66-54A54C303543Q36324477-DCA52F88-06FE-4187-9071-177C2EBA4AF2Q36516830-4939E9B4-4B42-4833-98CF-EB6F92C12C37Q36587580-F4A44EE0-971F-45B8-A5AC-49D429E0FF52Q37182894-C895AFA6-4BBC-4472-AF3B-2E4B0F9C799FQ37297990-797B860F-3F70-41D3-A13A-4430B40F5EB0Q38088303-17A50521-0F30-428A-ACB5-ECD1A6E07FB1Q38513773-96248B52-3B6A-4AD6-84B9-0DFF1A8C9C97Q38818339-5260196F-E7DF-4882-9266-CD6CD9059424Q39159019-820A4349-FECD-4F63-A419-336DB3B4F635Q39166790-FFF92A04-DBC0-4813-A723-2D7A884E4A73Q40604731-A1F9E1E0-2A58-4A43-B964-F82EC5021C95Q42132395-59F60B8C-714F-4533-B10E-20BED48D4702Q42257473-6F356916-0F60-45AC-A6C3-6D736F4E5011Q43099699-CD7CEF5F-6FFA-46F3-A80A-4DB370D267CAQ44676658-5BC29AE5-F474-44B3-B372-3C0C67DB6917Q45879842-D3EA7D13-75A7-4822-92CE-DFDA7440220AQ45880287-65FC048E-9FFF-4E5F-8B96-CD297FE75ECCQ45886003-7459C8DA-0B84-44C5-899D-410E10A79EC0
P2860
Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pre-clinical evaluation of thr ...... ol delivery to the ovine lung.
@en
type
label
Pre-clinical evaluation of thr ...... ol delivery to the ovine lung.
@en
prefLabel
Pre-clinical evaluation of thr ...... ol delivery to the ovine lung.
@en
P2093
P2860
P50
P356
P1433
P1476
Pre-clinical evaluation of thr ...... sol delivery to the ovine lung
@en
P2093
B Stevenson
E W F W Alton
P2860
P2888
P304
P356
10.1038/GT.2011.55
P577
2011-04-21T00:00:00Z